Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Fiche publication
Date publication
avril 2020
Journal
Liver international : official journal of the International Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
Tous les auteurs :
Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomášek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Ubreva ND, Widau RC, Shinozaki K, Yoshikawa R, Zhu AX
Lien Pubmed
Résumé
Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall survival (OS) benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥400 ng/mL by three prespecified age subgroups (<65, ≥65 to <75, ≥75 years).
Mots clés
VEGFR2, alpha-fetoprotein (AFP), elderly, hepatocellular carcinoma, ramucirumab, sorafenib intolerance
Référence
Liver Int.. 2020 Apr 12;: